0001387131-23-009352.txt : 20230807 0001387131-23-009352.hdr.sgml : 20230807 20230807083502 ACCESSION NUMBER: 0001387131-23-009352 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230807 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230807 DATE AS OF CHANGE: 20230807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 231145767 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_080723.htm CURRENT REPORT
0001430306 false 0001430306 2023-08-07 2023-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

yesw

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): August 7, 2023

 

 

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction 

of Incorporation) 

(Commission 

File Number)

(IRS Employer 

Identification No.) 

 

26 Main Street, Chatham, New Jersey 07928 

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

 

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On August 7, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study for its TNX-102 SL (cyclobenzaprine HCl sublingual tablet) product candidate as a potential treatment for fibromyalgia-type Long COVID. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01.Other Events.

 

On August 7, 2023, the Company announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for fibromyalgia-type Long COVID. Topline results for the PREVAIL study are expected in the third quarter of 2023.

 

Forward- Looking Statements 

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

  

Press Release of the Company, dated August 7, 2023

   

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: August 7, 2023 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 EX-99.01 2 ex99-01.htm PRESS RELEASE

 

Tonix Pharmaceuticals Holding Corp. 8-K

 

Exhibit 99.01

 

Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID

 

Topline Results Expected Third Quarter 2023

 

Long COVID Afflicts Approximately 19% of Patients Following COVID-191, and is Expected to be a Global Health Burden

 

Fibromyalgia-Type Long COVID with Multi-Site Pain Affects Approximately 40% of Long COVID Patients

 

CHATHAM, N.J., August 7, 2023 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for fibromyalgia-type Long COVID. Topline results for the PREVAIL study are expected in the third quarter of 2023.

 

“Approximately 40% of U.S. Long COVID patients have fibromyalgia-like multi-site pain symptoms based on our observational studies of Long COVID patients from the TriNetX claims database,”2,3 said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “In addition to multi-site pain, these individuals often suffer from one or more other symptoms typically associated with fibromyalgia such as fatigue, sleep disturbance, and brain fog. We have termed this subgroup, ‘Fibromyalgia-type Long COVID.’ Given our encouraging results with TNX-102 SL as a potential treatment for fibromyalgia4, we are testing TNX-102 SL as a bedtime medicine for the management of Fibromyalgia-type Long COVID. In completing this clinical milestone, marked by the last enrolled patient finishing their final visit, we can now begin to look forward to topline results from the 63-patient PREVAIL study later this quarter.”

 

Dr. Lederman continued, “TNX-102 SL improves sleep quality in fibromyalgia, and we believe this is the mechanism by which TNX-102 SL improves other symptoms, like multi-site pain.5 Recently, the U.S. National Institutes of Health (NIH) has identified improving sleep quality as a target for potential therapeutics for Long COVID6,7,8, consistent with the proposed mechanism of TNX-102 SL.

 

“Common symptoms of Long COVID, including multi-site pain, fatigue, unrefreshing sleep, and cognitive dysfunction, or ‘brain fog,’ are also hallmarks of conditions like fibromyalgia and chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME),”9 said Herbert Harris, M.D., Ph.D., Executive Vice President and Head of Translational Medicine of Tonix Pharmaceuticals. “Defining subgroups of Long COVID patients that overlap with fibromyalgia and CFS/ME is expected to facilitate the development of new treatments.4 It can be challenging to distinguish fibromyalgia and CFS/ME clinically, given the high level of symptom overlap between them.  Each of these conditions is defined by a constellation of symptoms, and there is no widely recognized diagnostic laboratory test that distinguishes them.”

 

Dr. Harris continued, “The recent identification of Long COVID subgroups in the National Institutes of Allergy and Infectious Diseases (NIAID)-sponsored RECOVER study10 was an important step. In their recent publication, cluster analysis of the symptom frequencies in the RECOVER study identified four subgroups of Long COVID patients. Cluster #4 represented approximately one-quarter of the population (28%) and reported the highest frequencies of pain (back pain (58%), joint pain (64%) or muscle pain (60%)), high frequencies of fatigue (94%) and ’Brain Fog,’ (94%) and a high level of impairment of Quality of Life. We believe Cluster #4 is a subgroup of Long COVID that shares many clinical features with fibromyalgia and

 

 

 

 

may involve common disease mechanisms. We also believe that Cluster #3, representing another approximately 29% of the RECOVER cohort, includes many patients with fibromyalgia-type Long COVID because 100% of that group suffer from ‘Brain Fog’, 94% experience fatigue and approximately one-third experience pain (back pain (32%), joint pain (36%) or muscle pain (34%)).”

 

Dr. Harris concluded, “With no FDA approved treatment for Long COVID, we understand the need to better understand long COVID and to develop treatments for subgroups of this unserved population of patients. Fibromyalgia has been recognized by the U.S. Food and Drug Administration (FDA) with three approved medicines. Consequently, measuring daily pain is a validated endpoint for FDA registrational studies in fibromyalgia. We believe that daily pain has the potential to be an endpoint for registrational studies in fibromyalgia-like long COVID.”

 

About the Phase 2 PREVAIL Study

 

The Phase 2 PREVAIL study is a 14-week double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of TNX-102 SL taken daily at bedtime in patients with multi-site pain associated with post-acute sequelae of SARS-CoV-2 infection (PASC). The trial is being conducted at approximately 30 sites in the U.S. The primary efficacy endpoint will be the change from baseline in the weekly average of daily self-reported worst pain intensity scores at the Week 14 endpoint. Key secondary efficacy endpoints include change from baseline in self-reported scores for sleep disturbance, fatigue, and cognitive function. Topline results are expected in the third quarter of 2023.

 

For more information, see ClinicalTrials.gov Identifier: NCT05472090.

 

About Long COVID or Post-Acute Sequelae of COVID-19 (PASC)

 

Post-acute sequelae of COVID-19, or PASC is the formal name for a condition now widely known as Long COVID. Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develops a chronic syndrome called Long COVID.11 These individuals experience a constellation of disabling symptoms long past the time of recovery from acute COVID-19. Most Long COVID patients who have been studied appear to have cleared the SARS-CoV-2 infection from their systems. The symptoms of Long COVID can include fatigue, sleep disorders, multi-site pain, fevers, shortness of breath, cognitive impairment described as “brain fog” or memory disturbance, gastrointestinal symptoms, anxiety, and depression. According to the Centers for Disease Control and Prevention (CDC), 1 in 13 adults in the U.S. (7.5%) have Long COVID symptoms.1 Long COVID is typically associated with moderate or severe COVID-19, but can occur after mild COVID-19 or even after asymptomatic SARS-CoV-2 infection. More than 40% of adults in the United States reported having COVID-19 in the past, and nearly one in five of those (19%) are currently still having symptoms of Long COVID.1 Long COVID is a chronic disabling condition that is expected to result in a significant global health and economic burden.12-15 In response to the urgent need for therapies that address Long COVID, Congress awarded $1.15 billion to the National Institutes of Health to study Long COVID in December 202016 The U.S. Department of Health and Human Services National Research Action Plan on Long COVID17, released in August 2022, addresses the overlap of Long COVID with CFS/ME, which, like fibromyalgia, is one of the overlapping chronic pain syndromes with central and peripheral sensitization.18 A published survey19 found comparable pain, fatigue, and functional impairment between Long COVID, fibromyalgia, and CFS/ME. This symptom overlap between these conditions has suggested that altered neurologic function is one of the leading hypotheses to explain

 

 

 

 

them.20 While the vaccines available in the U.S., through either FDA approval or under Emergency Use Authorization, have been shown to prevent acute COVID, their ability to prevent Long COVID is unknown. There is currently no approved drug for the treatment of Long COVID. Fibromyalgia-type Long COVID, like fibromyalgia and CFS/ME, appears to be one of several chronic overlapping pain conditions that have in common the neurological process called central and peripheral sensitization, which is increasingly known by the term nociplastic pain.

 

About TNX-102 SL

 

TNX-102 SL is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a multifunctional agent with potent binding and antagonist activities at the 5-HT2A-serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors, TNX-102 SL is in development as a daily bedtime treatment for fibromyalgia, Long COVID (formally known as post-acute sequelae of COVID-19 [PASC]), alcohol use disorder and agitation in Alzheimer’s disease. The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10,357,465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix’s proprietary TNX-102 SL composition. These patents are expected to provide TNX-102 SL, upon NDA approval, with U.S. market exclusivity until 2034/2035.

 

*TNX-102 SL is an investigational new drug and is not approved for any indication

 

1.NIH News Release. June 22, 2022. “Nearly One in Five American Adults Who Have Had COVID-19 Still Have ‘Long COVID’” https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm (accessed August 4, 2023).

2.Tonix Pharmaceuticals Press Release. Feb 22, 2023. https://ir.tonixpharma.com/news-events/press-releases/detail/1369/tonix-pharmaceuticals-describes-emerging-research-on-the

3.Harris, H. et al. Tonix data on file 2023

4.Lederman S, et al. Arthritis Care Res (Hoboken). 2023

5.Moldofsky H, et al. J Rheumatol. 2011. 38(12):2653-63

6.NIH News Release. July 31, 2023. “NIH launches long COVID clinical trials through the RECOVER Initiative, opening enrollment.” https://www.nih.gov/news-events/news-releases/nih-launches-long-covid-clinical-trials-through-recover-initiative-opening-enrollment (accessed August 4, 2023).

7.Howard, J. CNN. July 31, 2023. “Biden administration announces launch of HHS office focused on long Covid research” https://edition.cnn.com/2023/07/31/health/long-covid-research-office/index.html

8.Johnson, M and Goldstein A. Washington Post. July 31, 2023. “NIH announces long covid treatment studies with hundreds of patients” www.washingtonpost.com/health/2023/07/31/long-covid-treatment-studies-nih/

 

 

 

 

9.Clauw DJ, and Calabrese L. Ann Rheum Dis. 2023

10.Thaweethai T, et al. JAMA. 2023. 329(22):1934-1946

11.Clauw DJ, et al. Pain. 2020. 161(8):1694-1697

12.Briggs, A, and Vassall, A. Nature. 2021. 593(7860): 502-505

13.Nittas V, et al. Public Health Rev. 2022. 43:1604501

14.Davis, HE., et al. EClinicalMedicine. 2021. 38:101019

15.Martin C, et al. PLoS One. 2021. 16(12):e0260843

16.The NIH provision of Title III Health and Human Services, Division M--Coronavirus Response and Relief Supplemental Appropriations Act, 2021, of H.R. 133, The Consolidated Appropriations Act of 2021. The bill was enacted into law on 27 December 2020, becoming Public Law 116-260.

17.Department of Health and Human Services, Office of the Assistant Secretary for Health. 2022. National Research Action Plan on Long COVID, 200 Independence Ave SW, Washington, DC 20201. www.covid.gov/assets/files/National-Research-Action-Plan-on-Long-COVID-08012022.pdf

18.Maixner W, et al. J Pain. 2016. 17(9 Suppl):T93-T107

19.Haider S, et al. Pain. 2023. 164(2):385-401

20.Sutherland, S. Scientific American. 2023

 

Tonix Pharmaceuticals Holding Corp.*

 

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix Medicines, our commercial subsidiary markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead development CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia, having completed enrollment of a potentially confirmatory Phase 3 study in the third quarter of 2023, with topline data expected in the fourth quarter of 2023. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 proof-of-concept study has been completed, and topline results are expected in the third quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily oral formulation being developed as a treatment for major depressive disorder (MDD), that completed enrollment in a Phase 2 proof-of-concept study in the third quarter of 2023, with topline results expected in the fourth quarter of 2023. TNX-4300 (estianeptine) is a single isomer version of TNX-601, small molecule oral therapeutic in preclinical development to treat MDD, Alzheimer’s disease and Parkinson’s disease. Relative to tianeptine, estianeptine lacks activity on the µ-opioid receptor while maintaining activity in the rat Novel Object Recognition test in vivo and the ability to activate PPAR-β/δ and neuroplasticity in tissue culture. TNX-1900 (intranasal potentiated oxytocin), is in development for preventing headaches in chronic migraine, and has completed enrollment in a Phase 2 proof-of-concept study with topline data expected in the fourth quarter of 2023. TNX-1900 is also being studied in binge eating disorder, pediatric obesity and social anxiety disorder by academic collaborators under investigator-initiated INDs. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy

 

 

 

 

designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the third quarter of 2023. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals.

 

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

 

Tonix Medicines has contracted to acquire the Zembrace SymTouch and Tosymra registered trademarks. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc.

 

This press release and further information about Tonix can be found at www.tonixpharma.com.

 

Forward Looking Statements

 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

 

Investor Contact

 

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

Media Contact

 

Ben Shannon

ICR Westwicke

ben.shannon@westwicke.com

(919) 360-3039

 

 

 

 

 EX-101.SCH 3 tnxp-20230807.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20230807_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20230807_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 07, 2023
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tnxp-8k_080723_htm.xml IDEA: XBRL DOCUMENT 0001430306 2023-08-07 2023-08-07 iso4217:USD shares iso4217:USD shares 0001430306 false 8-K 2023-08-07 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 4X0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !A M1 =7)!Z;HJT #X 0 &@ @ &N$0 >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !A1 =799!YDAD! #/ P $P M @ &3$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" #=$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-8k_080723.htm ex99-01.htm tnxp-20230807.xsd tnxp-20230807_lab.xml tnxp-20230807_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tnxp-8k_080723.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tnxp-8k_080723.htm" ] }, "labelLink": { "local": [ "tnxp-20230807_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20230807_pre.xml" ] }, "schema": { "local": [ "tnxp-20230807.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20230807", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tnxp-8k_080723.htm", "contextRef": "AsOf2023-08-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://tonixpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tnxp-8k_080723.htm", "contextRef": "AsOf2023-08-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001387131-23-009352-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-23-009352-xbrl.zip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end